Galimedix, Inc. | WebDisclosure

Basculer en Français

11119	Companies
244822	Keywords
172892	Articles
132008	Press releases

Home
Companies
Galimedix, Inc.

PRESS RELEASE

published on 03/05/2026 at 14:00, 6 months 30 days ago

Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
Galimedix Therapeutics to present pre-clinical data on new oral amyloid beta modulator at AD/PD™ 2026 Conference, discussing GAL-201 prodrugs and improved pharmacokinetics

Galimedix Therapeutics Pre-clinical Data Pharmacokinetic Profile Oral Amyloid Beta Modulator AD/PD™ 2026 Conference
BRIEF

published on 12/04/2025 at 20:20, 10 months ago

Galimedix Therapeutics dévoile des résultats prometteurs de phase 1 pour le GAL-101

Résultats De La Phase 1 GAL-101 Traitement De La Maladie D'Alzheimer Barrière Hémato-encéphalique Planification De La Phase 2
BRIEF

published on 12/04/2025 at 20:20, 10 months ago

Galimedix Therapeutics Reveals Promising Phase 1 Results for GAL-101

Phase 1 Results GAL-101 Alzheimer’s Treatment Blood-brain Barrier Phase 2 Planning
PRESS RELEASE

published on 12/04/2025 at 20:15, 10 months ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Galimedix Therapeutics presents compelling Phase 1 study results at CTAD 2025, demonstrating excellent safety and pharmacokinetics of GAL-101, planning Phase 2 study in Alzheimer's disease

Alzheimer's Disease Galimedix Therapeutics GAL-101 Phase 1 Study CTAD 2025
BRIEF

published on 09/12/2025 at 13:25, 1 year ago

Galimedix Advances Alzheimer's Research with Successful Phase 1 Completion

Clinical Trial Galimedix Therapeutics Alzheimer's Research Phase 1 Study GAL-101 Molecule
BRIEF

published on 09/12/2025 at 13:25, 1 year ago

Galimedix fait progresser la recherche sur la maladie d'Alzheimer grâce à la réussite de la phase 1

Essai Clinique Galimedix Therapeutics Étude De Phase 1 Recherche Sur La Maladie D'Alzheimer Molécule GAL-101
PRESS RELEASE

published on 09/12/2025 at 13:20, 1 year ago

Progress in clinical development for Alzheimer´s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modul
Galimedix successfully completes Phase 1 study with GAL-101, a small molecule targeting amyloid beta in Alzheimer's disease. Phase 2 trial planned

Alzheimer's Disease Phase 2 Trial GAL-101 Phase 1 Study Galimedix
BRIEF

published on 05/21/2025 at 14:05, 1 year 4 months ago

Galimedix's GAL-201 Shows Promise in Alzheimer's Treatment

GAL-201 Neuroinflammation Alzheimer’s Treatment Amyloid-beta Synaptic Damage
BRIEF

published on 05/21/2025 at 14:05, 1 year 4 months ago

Le GAL-201 de Galimedix s'avère prometteur dans le traitement de la maladie d'Alzheimer

GAL-201 Neuroinflammation Traitement De La Maladie D'Alzheimer Bêta-amyloïde Dommages Synaptiques
PRESS RELEASE

published on 05/21/2025 at 14:00, 1 year 4 months ago

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease
Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

GAL-201 Galimedix Therapeutics Alzheimer’s Disease International Journal Of Molecular Sciences Neuroprotective Therapy

Accesswire

Published on 10/03/2026 at 02:35, 2 days 4 hours ago

Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 17:45, 2 days 13 hours ago

Sparton Provides Status Update
Published on 10/02/2026 at 13:50, 2 days 17 hours ago

AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 2 days 18 hours ago

Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 2 days 18 hours ago

Alaska Energy Metals Appoints Independent Director, Thomas Benson

View all ACCESSWIRE

EQS Group

Published on 10/05/2026 at 00:05, 7 hours 4 minutes ago

TerraMaster lance sa saison de mise à niveau du stockage avec jusqu’à 30 % de réduction à l’occasion des Prime Big Deal Days
Published on 10/04/2026 at 06:05, 1 day 1 hour ago

Blokees Debuts 90+ New Products at Wonder Festival Shanghai 2026
Published on 10/04/2026 at 05:15, 1 day 1 hour ago

SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
Published on 10/03/2026 at 15:45, 1 day 15 hours ago

Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 2 days 7 hours ago

IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY

Les Echos

Published on 10/05/2026 at 07:00, 9 minutes ago

Schneider Electric to acquire PTC, creating the next level of Energy and Industrial Intelligence
Published on 10/05/2026 at 07:00, 9 minutes ago

Schneider Electric va acquérir PTC, portant l’Intelligence Énergétique et Industrielle à un nouveau niveau
Published on 10/02/2026 at 17:45, 2 days 13 hours ago

Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 2 days 13 hours ago

Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 2 days 13 hours ago

Peugeot Invest - Déclaration du nombre d'actions et de droits de vote

View all LES ECHOS COMFI WIRE